Search
Ramucirumab
go.drugbank.com/drugs/DB05578ApprovedInvestigationalBy binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stimulated receptor phosphorylation and downstream ligand-induced proliferation, … In contrast to other agents directed against VEGFR-2, ramucirumab binds a specific epitope on the extracellular domain of VEGFR-2, thereby blocking all VEGF ligands from binding to it.
Insulin glulisine
go.drugbank.com/drugs/DB01309Approvedcells that the body is no longer able to produce insulin on its own. … Insulin is an important treatment in the management of Type 1 Diabetes (T1D) which is caused by an autoimmune reaction that destroys the beta cells of the pancreas, resulting in the body not being able
Acetrizoic acid
go.drugbank.com/drugs/DB09347ApprovedWithdrawn[A32135] It was first synthesized by Wallingford in 1953[A32136] and it was filled in the FDA by the Johnson & Johnson subsidiary, Cilag Chemie AG, on February 8th, 1978.
Griseofulvin
go.drugbank.com/drugs/DB00400ApprovedVet approvedGriseofulvin may be given by mouth in the treatment of tinea infections.
Alpelisib
go.drugbank.com/drugs/DB12015ApprovedInvestigationalAlpelisib was designed to target this enzyme that appears to be mutated at a rate of nearly 30% in human cancers, leading to hyperactivation. … Alpelisib was granted FDA approval on 24 May 2019.
Lanthanum carbonate
go.drugbank.com/drugs/DB06792ApprovedIt is used to treat elevated phosphate levels, primarily in patients with chronic kidney disease, by binding to dietary phosphate and preventing its absorption in the intestine.[L50733] … Lanthanum carbonate is a phosphate binder marketed under the trade name _Fosrenol_ by Shire Pharmaceuticals.
Efmoroctocog alfa
go.drugbank.com/drugs/DB11607ApprovedInvestigationalVIII, but does not contain the B-domain, which has no known biological function, and [DB13192], which is purified endogenous Factor VIII from human pooled blood and contains both A- and B-subunits. … To date, no confirmed inhibitory autoantibodies were seen in previously treated patients included in clinical studies and treatment-emergent adverse events were generally consistent with those expected
Droperidol
go.drugbank.com/drugs/DB00450ApprovedInvestigationalVet approvedIt is used in conjunction with an opioid analgesic such as fentanyl to maintain the patient in a calm state of neuroleptanalgesia with indifference to surroundings but still able to cooperate with the … A butyrophenone with general properties similar to those of haloperidol.
Sodium carbonate
go.drugbank.com/drugs/DB09460ApprovedWithdrawnSodium Carbonate is the disodium salt of carbonic acid with alkalinizing property. When dissolved in water, sodium carbonate forms carbonic acid and sodium hydroxide. As a strong base, sodium hydroxide neutralizes gastric acid thereby ac...
Mixtures: ENO, ENO ORANGEEplerenone
go.drugbank.com/drugs/DB00700ApprovedInvestigationalThe resulting increased plasma renin activity and aldosterone circulating levels do not overcome the effects of eplerenone. … Eplerenone selectively binds to recombinant human mineralocorticoid receptors relative to its binding to recombinant human glucocorticoid, progesterone and androgen receptors.